Prostate Cancer in Patients With High Prostate-Specific Antigen Levels but Otherwise Very-Low-Risk Disease Behaves Like Prostate Cancer in High-Risk Patients

Matthew M. Gestaut, Jessica E. Pruszynski, Gregory P. Swanson

Research output: Contribution to journalArticlepeer-review


A review was conducted of divergent-risk prostate cancer patients treated with radiation. These patients exhibited a low-volume, low-risk Gleason score but high-risk prostate-specific antigen level. The clinical outcomes were compared with those of classically high-risk and ultra-low risk patients. The disease prognosis of the divergent-risk group was equally poor as their classically high-risk counterparts. These patients should be treated similarly to classically high-risk patients. Introduction Rarely, patients with prostate cancer present with prostate-specific antigen (PSA) scores > 20 ng/mL but with otherwise very-low-risk disease. Oncologists have debated whether the malignancies in these patients behave more comparably to low-risk or high-risk disease. Our objective was to elucidate the behavior of these malignancies. Materials and Methods A retrospective review was conducted of prostate cancer patients treated with radiation from 2000 to 2013. The inclusion criteria for very-low-risk disease included stage T1a-T1c, Gleason score ≤ 6, ≤ 3 positive cores, ≤ 50% involvement of any core, and PSA level < 10 ng/mL. The divergent-risk group met all the same criteria but had a PSA score of 20 to 80 ng/mL. The high-grade, low-volume group consisted of patients with stage T1c-T2a, PSA level < 20 ng/mL, Gleason score of 4+4, and < 4 positive cores. Treatment failure was defined as a PSA nadir plus 2 ng/mL. Results A total of 18, 60, and 19 patients were in the divergent, low-risk, and high-grade groups, respectively. Biochemical progression-free survival at 5 years was 71.3% for the divergent group, 68.8% for the high-grade group, and 98.3% for the low-risk group. The biochemical failure rate for the divergent group differed significantly from the low-risk group (P = .021), and that for the low-risk group was significantly different from that of the high-grade group (P = .025). However, the divergent group did not appear different from the high-grade group (P = .53). Conclusion The results of our study have shown that the disease prognosis for the divergent-risk group is worse than that for the very-low-risk disease group and does not appear to be different from that for the low-volume, high-grade disease group. Oncologists should be aware that the outcomes for divergent patients are similarly poor to their low-volume, classically high-risk counterparts.

Original languageEnglish (US)
Pages (from-to)445-449
Number of pages5
JournalClinical Genitourinary Cancer
Issue number4
StatePublished - Aug 2017


  • Divergent risk
  • High PSA
  • High-risk disease
  • Low-volume disease
  • Very-low-risk prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Prostate Cancer in Patients With High Prostate-Specific Antigen Levels but Otherwise Very-Low-Risk Disease Behaves Like Prostate Cancer in High-Risk Patients'. Together they form a unique fingerprint.

Cite this